Tag: GlobeNewswire

SHANGHAI, Nov. 02, 2026 (GLOBE NEWSWIRE) — Sigenergy, a global pioneer in next-generation energy storage solutions, has just been designated as a Tier 1 Energy Storage Manufacturer by BloombergNEF (BNEF) for the fourth quarter of 2026. This prestigious benchmark highlights Sigenergy’s exceptional financial stability, robust bankability, and field-proven product reliability across major global markets.

BloombergNEF’s Tier 1 rating is widely recognized as one of the most rigorous independent evaluation frameworks in the renewable energy sector. Designed to provide transparent market intelligence, the Tier 1 designation assesses manufacturers based on stringent criteria including financial health, demonstrated project delivery track records, and strict quality standards.

For global investors, Engineering, Procurement, and Construction (EPC) contractors, project developers, and asset owners, Sigenergy’s Tier 1 status offers strong assurance of long-term operational stability and technical performance, facilitating smoother project financing and risk mitigation across the energy value chain.

The Tier 1 status validates Sigenergy’s rapid worldwide growth, fueled by continuous R&D investment and its visionary “AI in All” strategy. By integrating artificial intelligence into its flexible, modular product architecture, Sigenergy delivers highly reliable, innovative energy storage solutions tailored for diverse applications, ranging from Commercial & Industrial (C&I) projects to complex, utility-scale power plants.

This milestone reinforces Sigenergy’s commitment to empowering a broader spectrum of global customers, asset owners, and partners with scalable efficiency, robust safety, and long-term project value.

About Sigenergy
Founded in 2022 and headquartered in Shanghai, Sigenergy (6656.HK) is a technology-driven company focused on innovation in the new energy sector. Leveraging advanced digital intelligence and a highly skilled talent base, the company has expanded across photovoltaic(PV)generation, smart energy storage and high-efficiency electric vehicle (EV) charging solutions.

Guided by its “AI in All” strategy, Sigenergy integrates artificial intelligence across its product ecosystem to deliver safer, smarter and more efficient energy solutions for households and businesses worldwide.

For more information, visit: www.sigenergy.com

Media Contact 
Tracy Li Email: tracy.li@sigenergy.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/df0a94ea-9736-49f7-8fc7-9146ad7fbd21

Press Release no. 07/2026

cBrain expands U.S. market access through partnership with Carahsoft Technology Corporation

Copenhagen, November 2, 2026

cBrain^® has entered a distribution partnership with Carahsoft Technology Corp., The Trusted Government IT Solutions Provider^®.

As a first step in the partnership, Carahsoft Technology Corp. has made cBrain’s F2 software platform and related services available through NASA Solutions for Enterprise-Wide Procurement (SEWP V).

For cBrain, the partnership represents an important commercial milestone. By simplifying procurement and reducing the time required to enter into contracts with Federal customers, it strengthens cBrain’s ability to convert growing interest in F2 into commercial agreements.

Simplifying federal procurement and accelerating market access

NASA SEWP V is a Government-Wide Acquisition Contract (GWAC) managed by NASA, providing U.S. Federal agencies and authorized contractors with a streamlined procurement process for commercial IT products and related services.

Through Carahsoft Technology Corp.’s SEWP V contract, U.S. Federal agencies can now procure cBrain’s F2 platform and related services using an established Government procurement vehicle.

Carahsoft Technology Corp. serves federal, state and local government agencies, as well as education, healthcare and private sector organizations, through an extensive network of technology vendors, resellers and systems integrators. The partnership provides cBrain with access to an established U.S. government distribution ecosystem.

Supporting cBrain’s continued U.S. expansion

The agreement marks another important milestone in cBrain’s U.S. expansion strategy, following the recent establishment of cBrain Inc., a wholly owned U.S. subsidiary, and its registration in the U.S. federal government’s System for Award Management (SAM.gov), announced on October 22, 2026.

cBrain has made significant progress in the U.S. market during 2026. Following a successful pilot project, the company was awarded its first contract with the State of California in August 2026. In parallel, cBrain has initiated activities with U.S. federal and state government agencies.

With the establishment of cBrain Inc., registration in SAM.gov and now the Carahsoft Technology Corp.’s partnership and NASA SEWP V listing, cBrain continues to build the commercial foundation for scaling its activities in the U.S. government market.

The U.S. market represents a strategic growth opportunity for cBrain. F2 is a highly configurable, AI-enabled commercial off-the-shelf (COTS) software platform that combines case management, workflow automation, document management and digital services in one fully integrated solution.

Built specifically for government, F2 enables public authorities to accelerate digital transformation through standard software, reducing the complexity, cost and risk associated with traditional custom-built IT solutions.

About cBrain

cBrain® (NASDAQ: CBRAIN) is pioneering a new generation of integrated enterprise software, built specifically for government.

The cBrain F2 software brings together case management, document management, workflow automation, digital services and artificial intelligence in one unified platform. Delivered as commercial off-the-shelf (COTS) software, F2 enables government organizations to accelerate digital transformation without the complexity and cost of traditional custom-built IT systems.

F2 is used by more than 75 public authorities in Denmark, including the Danish government ministries, providing a proven foundation for international expansion.

Building on Denmark’s position as a global leader in digital government, cBrain is bringing the Danish model of digital government to the world. Today, F2 is used by government organizations across five continents, demonstrating how the Danish model can be reused and scaled internationally through standard software.

Best regards

Per Tejs Knudsen, CEO

Inquiries regarding this Press Release may be directed to 

Lars Møller Christiansen, CFO & Head of Investor Relations, cBrain A/S, ir@cbrain.com, +45 24429300

Attachment

• Press Release no. 2026-07 (Carahsoft)

Company Announcement

Copenhagen, 2 November 2026
No. 66/2026

ISS A/S, a leading workplace experience and facility management company, announced on 19 February 2026 a new share buyback programme, see company announcement no. 10/2026. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Regulation.

Through the programme, ISS wishes to redistribute excess cash to shareholders. The purpose of the share buy-back programme is to (i) reduce the share capital and (ii) meet obligations arising from ISS’ share-based incentive programmes.

Under the programme, ISS will repurchase shares for a maximum consideration of DKK 3.1 billion, including approx. DKK 1.25 billion related to the completed first tranche, over a 12-month period from 19 February 2026 to 22 February 2027 at the latest, both days inclusive. The second tranche of up to DKK 1.85 billion commenced on 11 August 2026 and will complete no later than 22 February 2027.

The following transactions have been made under the programme:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated, last announcement	7,332,975	265.72	1,948,491,427
26 October 2026	51,225	292.28	14,972,043
27 October 2026	53,000	291.61	15,455,330
28 October 2026	48,062	293.71	14,116,290
29 October 2026	22,779	288.29	6,566,958
30 October 2026	9,000	288.36	2,595,240
Accumulated under the programme	7,517,041	266.35	2,002,197,288

Following the transactions stated above, ISS A/S owns a total of 7,265,416 treasury shares corresponding to 4.54% of the total share capital.

In accordance with the Market Abuse Regulation, the details of each transaction made under the share buyback programme are enclosed.

ISS is a leading, global provider of workplace and facility service solutions. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. ISS has more than 325,000 employees around the globe, who we call “placemakers”. In 2025, Group revenue was DKK 84.7 billion. For more information on the ISS Group, visit www.issworld.com

Attachments

• ISS announcement – SBB week 44
• Appendix_Company_Announcement_NO_44-2026

Company announcement no. 53 2026

Danske Bank Bernstorffsgade 40 DK-1577 København V Tel. + 45 33 44 00 00 02 November 2026 Page 1 of 2

Danske Bank share buy-back programme: transactions in week 44

On 5 February 2026, Danske Bank A/S announced a share buy-back programme for a total of DKK 4.5 billion, with a maximum of 45,000,000 shares, in the period from 9 February 2026 to 29 January 2027, at the latest, as described in company announcement no. 6 2026.

The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions were made under the share buy-back programme in week 44:

	Number of shares	VWAP DKK	Gross value DKK
Accumulated, last announcement	10,800,666	342.2702	3,696,746,086
26 October 2026	16,359	344.2755	5,632,003
27 October 2026	15,645	347.5929	5,438,091
28 October 2026	15,399	353.7779	5,447,826
29 October 2026	15,254	357.1419	5,447,843
30 October 2026	17,767	346.4075	6,154,622
Total accumulated over week 44	80,424	349.6516	28,120,384
Total accumulated during the share buyback programme	10,881,090	342.3248	3,724,866,470

With the transactions stated above, the total accumulated number of own shares under the share buy-back programme corresponds to 1.334% of Danske Bank A/S’ share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.

Danske Bank

Contact: Claus Ingar Jensen, Head of Group Investor Relations, tel. +45 25 42 43 70

Nasdaq Copenhagen	Number of shares	VWAP DKK	Gross value DKK
26 October 2026	8,517	344.2024	2,931,572
27 October 2026	9,326	347.2056	3,238,039
28 October 2026	8,625	353.5571	3,049,430
29 October 2026	9,139	357.0754	3,263,312
30 October 2026	10,980	346.3664	3,803,103
Total accumulated over week 44	46,587	349.5708	16,285,456
Total accumulated during the share buyback programme	6,929,434	342.3968	2,372,616,369

CBOE Europe	Number of shares	VWAP DKK	Gross value DKK
26 October 2026	7,842	344.3549	2,700,431
27 October 2026	6,319	348.1644	2,200,051
28 October 2026	6,774	354.0590	2,398,396
29 October 2026	6,115	357.2414	2,184,531
30 October 2026	6,787	346.4741	2,351,520
Total accumulated over week 44	33,837	349.7629	11,834,929
Total accumulated during the share buyback programme	3,951,656	342.1983	1,352,250,073

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

• Danske Bank Company Announcement_EN_Weekly SBB announcment

HANGZHOU, China, Nov. 02, 2026 (GLOBE NEWSWIRE) — DSC Holdings Ltd. (“DSC” or the “Company”) (Nasdaq: DSC), the AI application infrastructure for China’s used car industry, today released its inaugural China Used Car Industry White Paper (First Half of 2026). Leveraging its flagship DaFengChe system, which holds over 90% market share in China’s used car dealer operating system market, DSC draws on its extensive proprietary operating data and public industry statistics to provide unique insights into the dynamics shaping China’s used car market.

The white paper conducted an in-depth examination of used car transaction volumes, vehicle pricing, residual values, dealer operating performance and cross-region circulation, revealing industry trends and observations that public statistics alone do not reveal.  The publication underscores DSC’s commitment to advancing industry transparency and data-driven decision-making, while demonstrating the value of its granular industry data and digital infrastructure.

“The Chinese used car market does not lack vehicles or demand. What the industry needs to overcome is the inefficiency in the arduous process of moving used cars from the selling consumers, through the large community of dispersed independent dealers, to the buying consumers,” said Ms. Qin Zou, director and chief financial officer of DSC. “The key to better used car commerce is shifting as many market participants as possible from traditional experience-based and relationship-driven practices toward data-driven decision-making and AI-enabled operations, whether they are used car dealers or inspectors or transporters.”

Key Findings from the White Paper

1. Used Car Transactions Near New Car Sales; Turnover Rate Remains Low Relative to Mature Markets
China’s used car transaction volume reached 9.71 million vehicles in the first half of 2026, up 1.5% year over year and equivalent to 98% of domestic new car sales, which fell 21.1% to 9.92 million. The jump in the used-to-new ratio, from roughly 0.74 for full-year 2025, therefore reflects weaker new car sales rather than stronger used car demand. China’s annualized used car turnover rate, measured as annualized used car transactions as a percentage of the nation’s total vehicle population of 371 million, stood at 5.2%, compared with 8.1% in Japan, 8.5% in Europe and 14.7% in the U.S. The white paper notes that long-term used car volume is driven by the size and age of the vehicle fleet and by how soon owners resell their cars: the age at which fuel vehicle owners first replace their cars has declined steadily over the past decade, and NEV owners replace their vehicles much sooner. In the near term, however, intense new car price competition has weighed on used car demand, particularly for near-new vehicles, whose share of transactions fell from 28.2% in the second half of 2023 to 24.9% in the first half of 2026.

2. Price Competition Is Reshaping Residual Values: Brand Premiums Narrow While Vehicle Condition Matters More
DSC’s used car price index declined from a baseline of 100 in the first half of 2022 to 76.9 in the first half of 2026, a fall of 23.1%, roughly twice the 11.2% decline in DSC’s new car price index over the same period, as new car price cuts were amplified in the used car market. Brand premiums have compressed sharply: for vehicles less than three years old, the residual value gap between luxury and domestic brands narrowed from 8.7 to 3.9 percentage points, and the premium of non-luxury joint venture brands over domestic brands shrank from 4.3 to 1.2 percentage points. Vehicle condition has become a more important pricing variable than brand: among three- to five-year-old vehicles, those in excellent condition retain 12 to 13 percentage points more of their value than those in average condition. Residual values of younger NEVs are improving, with the gap between one-year-old NEVs and comparable fuel vehicles narrowing from 5.8 to 2.5 percentage points, although older NEV models still depreciate far more steeply, retaining only 11.6% of their value at eight years versus 27.9% for fuel vehicles.

3. Dealer Margins Are Compressing and Small Dealers Are Being Squeezed Out
DSC’s dealer gross margin index fell from 100 in January 2026 to 85.6 in June, a steeper decline than the 3.9% drop in retail prices over the same months, as dealers cut prices to accelerate turnover. The share of profitable dealers fell by 10 to 16 percentage points year over year across all size tiers; among dealers selling fewer than 50 vehicles a year, only 28.7% were profitable, down from 40.7% a year earlier. Consolidation is under way: dealers selling fewer than 50 vehicles a year fell from 70.3% of the dealer base in the first half of 2022 to 56.6%, while those selling more than 200 vehicles rose from 4.1% to 10.8%. Dealer performance now hinges less on brand than on smart procurement decisions, both which vehicles to buy and at what price, together with fast turnover and high capital efficiency, all of which require dealers to upgrade their operating methods.

4. NEVs and Cross-Regional Circulation Are Reshaping Vehicle Supply
NEVs accounted for 7.6% of used car transactions in the first half of 2026, up 2.4 percentage points year over year but still well below their 51.3% share of new car sales, reflecting the young age of China’s NEV fleet rather than weak demand. With 48.97 million NEVs on the road, or 13.2% of the vehicle population, most of them less than five years old, a large wave of NEV supply is expected to enter the used car market over the next several years, shifting the used car mix away from joint venture fuel vehicles, which still account for 55.7% of transactions, toward domestic-brand NEVs. Cross-city circulation continued to deepen: the cross-city circulation rate rose from 35.3% in the first half of 2022 to 41.6% in the first half of 2026. Megacities Beijing and Shanghai saw outbound transfer rates of 68.6% and 71.2%, respectively.

Industry Outlook
The white paper expects the market to remain in a relatively stable phase in the near term without significant movements in either direction. Supporting factors include shorter NEV replacement cycles, a growing pool of younger first-time buyers, with China’s 533 million licensed drivers far exceeding its 371 million vehicles, and the gradual easing of new car price competition, which is expected to bring part of the diverted demand back to the used car market. Offsetting factors include scrappage-based trade-in subsidies that divert older vehicles from circulation. With brand premiums compressed, pricing is shifting from brand and model year toward the condition, specification and battery health of each individual vehicle, and dynamic, data-driven pricing is becoming a basic requirement for dealers rather than a competitive advantage.

Leveraging Industry Data to Advance AI Applications
The white paper highlights opportunities for AI to improve efficiency across China’s used car market, particularly in vehicle matching, valuation, dynamic pricing and inventory management. DSC believes its extensive dealer network, proprietary operating data and established digital infrastructure provide a strong foundation for developing AI solutions that address these industry challenges.

“AI’s competitive advantage lies not in technology alone, but in combining proprietary data, industry expertise and real-world applications,” Ms. Zou added. “Building on more than a decade of experience in digitizing China’s used car industry, DSC has in recent months been providing the used car industry with a range of AI-enabled solutions that improve dealer operations and contribute to a more efficient used car market.”

About DSC
DSC is the AI application infrastructure for China’s used car industry. The Company has held over 90% market share in operating systems for China’s used car dealers since 2021, according to China Insights Consultancy, giving it nation-wide dealer connection and massive, granular, proprietary, real-time industry data. Building on this digital foundation, DSC further supports used car dealers with essential transaction services across their workflows. DSC’s services also engage and benefit thousands of dealers’ collaborators, such as inspectors, transporters and other internet platforms, creating an ecosystem with used car dealers at its center.

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this announcement is as of the date of this announcement, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
DSC IR Department
Email: ir@souche.com

The Blueshirt Group
Ms. Feifei Shen
Email: dsc@blueshirtgroup.co

Schindellegi, Switzerland – 2 November 2026

Trifork Group AG
Company announcement no. 68/2026

Weekly report on share buyback

On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026.

Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million).

Under the program, the following transactions have been made:

Date	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Total beginning	592,812	99.94	59,248,243
26 October 2026	2,900	101.23	293,567
27 October 2026	2,369	100.36	237,753
28 October 2026	2,700	101.33	273,591
29 October 2026	2,700	96.21	259,767
30 October 2026	3,100	101.00	313,100
Accumulated	606,581	99.95	60,626,021

A detailed overview of the daily transactions can be found here: https://investor.trifork.com/trifork-shares/.

With the transactions stated above, the total accumulated amount of treasury shares acquired under the current share buyback program corresponds to 3.1% of the share capital of Trifork Group AG. Trifork Group owns 872,997 treasury shares in total, corresponding to 4.4% of the share capital.

Investor & Media contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 7317

About Trifork Group
Trifork (Nasdaq Copenhagen: TRIFOR) is a global technology company specializing in designing, building, and operating advanced software for enterprise and public sector customers. With 1,122 FTEs across 16 countries, Trifork serves as an end-to-end technology partner to organizations in complex and regulated industries, including public administration, healthcare, financial services, energy, and aviation.

Learn more at trifork.com.

Attachment

• CA_68_2026_Buyback

Total Voting Rights

Shell plc (the “Company”) announces, in compliance with Rule 5.6.1 of the FCA’s Disclosure Guidance and Transparency Rules that, as at 30 October 2026 the Company’s capital consisted of 5,701,440,412 ordinary shares of €0.07 each, with voting rights. The Company held no shares in Treasury.

Accordingly, the total number of voting rights in the Company was 5,701,440,412. This figure may be used by shareholders as the denominator for the calculations by which they determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA Disclosure Guidance and Transparency Rules.

Enquiries

Shell Media Relations
International +44 (0)207 934 5550; U.S. and Canada: Contact form

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications

Aaron Tansy, M.D., appointed as Vice President, Development Franchise Head, Neurology, brings complementary expertise in neurology and global clinical development

ZUG, Switzerland, November 2, 2026 — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today announced the appointment of  Björn Tackenberg, M.D., Ph.D., FEAN, FAAN and Professor of Neurology as its new Chief Scientific Officer (CSO). Prof. Tackenberg will lead Oculis’ global integrated scientific strategy, research portfolio development and value creation, expansion into novel drug candidates, and related strategic scientific partnerships and external engagements. His initial priorities will focus on advancing Oculis’ lead asset Privosegtor through the PIONEER registrational program and evaluating its therapeutic potential in acute multiple sclerosis (MS) relapses and additional neurological indications.

Prof. Tackenberg joins Oculis from Roche, where he served as Head of Integrative Neuroscience & Medical Practice, encompassing clinical development plans and study design, biomarker development and evidence-generation strategies, and strategic partnerships with academic and scientific institutions. Previously, he served as Head of the Center of Neuroimmunology and Vice-Chair of the Department of Neurology at Marburg University in Germany from 2008 to 2019. During his tenure, he established a clinical trials unit that conducted more than 75 randomized controlled trials in autoimmune indications and a tertiary reference center for complex autoimmune treatments. As an experienced and successful industry leader, board-certified neurologist and physician-scientist, Prof. Tackenberg brings deep clinical and scientific expertise in MS, neuroimmunology, neurodegenerative and neuromuscular diseases. He has authored or co-authored over 135 original publications, as well as treatment guidelines for MS, myasthenia gravis and inflammatory neuropathies. His career bridges basic neuroscience and academic clinical neurology, translational research, pharmaceutical and biomarker development, and scientific and medical affairs.  Prof. Tackenberg is a Fellow of both the European Academy of Neurology and the American Academy of Neurology.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “Oculis is building a world-leading neuro-ophthalmology and neurology franchise. We are exceptionally pleased to welcome Björn as Chief Scientific Officer and Aaron as Development Franchise Head, Neurology, as we advance Privosegtor through the PIONEER registrational program, and prepare to explore its potential in acute MS relapses and other neurological indications. Björn and Aaron bring highly complementary leadership across scientific strategy, development execution, and translational advancement. Their collective experience in neurology, neuroimmunology, neuromuscular and neurodegenerative diseases spanning academic research, clinical practice and pharmaceutical development will materially strengthen Oculis’ ability to translate emerging insights into new therapeutic opportunities.”

Björn Tackenberg, M.D., Chief Scientific Officer of Oculis, added: “I am excited to join Oculis at this pivotal time in the Company’s growth. Privosegtor is a highly promising innovation with the potential to advance neuroprotection, and the opportunity to help shape its development is invaluable. Building on the PIONEER program in neuro-ophthalmology, I look forward to working with the Oculis team and external scientific partners to explore Privosegtor’s potential in acute MS relapses and other neurological indications, translate research into meaningful evidence for patients, and evaluate new opportunities to address significant unmet needs for people living with neurological conditions.”

Aaron Tansy, M.D., recently joined Oculis as Vice President, Development Franchise Head, Neurology. A board-certified neurologist, Dr. Tansy brings clinical research and drug development experience spanning early-stage studies through commercial approval, including programs in MS, amyotrophic lateral sclerosis (ALS), autoimmune disorders and rare diseases. His experience includes global clinical development planning, Phase 1–3 trial design and execution, medical and safety oversight, and interactions with U.S. and European regulatory authorities from investigational applications through marketing submissions. He most recently served as Executive Medical Director, Clinical Development at PTC Therapeutics and previously held clinical development roles at Ovid Therapeutics and Teva Pharmaceutical Industries.

– Ends –

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; and Oculis’ future development plans, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications

Aaron Tansy, M.D., appointed as Vice President, Development Franchise Head, Neurology, brings complementary expertise in neurology and global clinical development

ZUG, Switzerland, November 2, 2026 — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today announced the appointment of  Björn Tackenberg, M.D., Ph.D., FEAN, FAAN and Professor of Neurology as its new Chief Scientific Officer (CSO). Prof. Tackenberg will lead Oculis’ global integrated scientific strategy, research portfolio development and value creation, expansion into novel drug candidates, and related strategic scientific partnerships and external engagements. His initial priorities will focus on advancing Oculis’ lead asset Privosegtor through the PIONEER registrational program and evaluating its therapeutic potential in acute multiple sclerosis (MS) relapses and additional neurological indications.

Prof. Tackenberg joins Oculis from Roche, where he served as Head of Integrative Neuroscience & Medical Practice, encompassing clinical development plans and study design, biomarker development and evidence-generation strategies, and strategic partnerships with academic and scientific institutions. Previously, he served as Head of the Center of Neuroimmunology and Vice-Chair of the Department of Neurology at Marburg University in Germany from 2008 to 2019. During his tenure, he established a clinical trials unit that conducted more than 75 randomized controlled trials in autoimmune indications and a tertiary reference center for complex autoimmune treatments. As an experienced and successful industry leader, board-certified neurologist and physician-scientist, Prof. Tackenberg brings deep clinical and scientific expertise in MS, neuroimmunology, neurodegenerative and neuromuscular diseases. He has authored or co-authored over 135 original publications, as well as treatment guidelines for MS, myasthenia gravis and inflammatory neuropathies. His career bridges basic neuroscience and academic clinical neurology, translational research, pharmaceutical and biomarker development, and scientific and medical affairs.  Prof. Tackenberg is a Fellow of both the European Academy of Neurology and the American Academy of Neurology.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “Oculis is building a world-leading neuro-ophthalmology and neurology franchise. We are exceptionally pleased to welcome Björn as Chief Scientific Officer and Aaron as Development Franchise Head, Neurology, as we advance Privosegtor through the PIONEER registrational program, and prepare to explore its potential in acute MS relapses and other neurological indications. Björn and Aaron bring highly complementary leadership across scientific strategy, development execution, and translational advancement. Their collective experience in neurology, neuroimmunology, neuromuscular and neurodegenerative diseases spanning academic research, clinical practice and pharmaceutical development will materially strengthen Oculis’ ability to translate emerging insights into new therapeutic opportunities.”

Björn Tackenberg, M.D., Chief Scientific Officer of Oculis, added: “I am excited to join Oculis at this pivotal time in the Company’s growth. Privosegtor is a highly promising innovation with the potential to advance neuroprotection, and the opportunity to help shape its development is invaluable. Building on the PIONEER program in neuro-ophthalmology, I look forward to working with the Oculis team and external scientific partners to explore Privosegtor’s potential in acute MS relapses and other neurological indications, translate research into meaningful evidence for patients, and evaluate new opportunities to address significant unmet needs for people living with neurological conditions.”

Aaron Tansy, M.D., recently joined Oculis as Vice President, Development Franchise Head, Neurology. A board-certified neurologist, Dr. Tansy brings clinical research and drug development experience spanning early-stage studies through commercial approval, including programs in MS, amyotrophic lateral sclerosis (ALS), autoimmune disorders and rare diseases. His experience includes global clinical development planning, Phase 1–3 trial design and execution, medical and safety oversight, and interactions with U.S. and European regulatory authorities from investigational applications through marketing submissions. He most recently served as Executive Medical Director, Clinical Development at PTC Therapeutics and previously held clinical development roles at Ovid Therapeutics and Teva Pharmaceutical Industries.

– Ends –

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; and Oculis’ future development plans, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

To Nasdaq Copenhagen A/S

Executive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 2 November 2026

Company Announcement 02.11.2026  

Prepayments, Realkredit Danmark A/S

Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 30 October 2026. Please find the data in the attached file.

The information will also be available on www.rd.dk.

Yours sincerely

The Executive Management

Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.

Attachment

• 20261102 Bilag